MeiraGTx - About the company
MeiraGTx is a public company based in New York City (United States), founded in 2015 by Sam Waksal. It operates as a Developer of gene therapies for ocular and neurodegenerative diseases. MeiraGTx has raised an undisclosed amount in funding. The company has 3636 active competitors, including 1268 funded and 882 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Alnylam and Sana Biotechnology.
Company Details
Developer of gene therapies for ocular and neurodegenerative diseases. Its drug pipeline includes AAV-RPGR to treat the most common form of X-linked retinitis pigmentosa, AAV-RPE65 to treat rare pediatric disease, and AAV-GAD is an investigational gene therapy to treat Parkinson's disease.
- Website
- meiragtx.com
- Social
- Email ID
- *****@meiragtx.com
Key Metrics
Founded Year
2015
Location
New York City, United States
Stage
Public
Latest Funding Round
Investors
Ranked
92nd among 3636 active competitors
Annual Revenue
$50M - $100M as on Dec 31, 2025
Employee Count
419 as on Jun 30, 2026
Exit Details
Public
Legal entities associated with MeiraGTx
MeiraGTx is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
MEIRAGTX HOLDINGS PLC CIN: 98-1448305 , United States, Active | $50M - $100M (As on Dec 31, 2025) | 358 (As on Dec 31, 2022) | - |
MeiraGTx's IPO details
MeiraGTx got listed on Jun 08, 2018.
Click here to take a look at MeiraGTx's IPO in detail
Sign up to download MeiraGTx's company profile
MeiraGTx's funding and investors
MeiraGTx has raised funding over 3 rounds. Its latest funding round was a Post IPO round on Oct 30, 2023 for $*****. 1 investor participated in its latest round. MeiraGTx has 7 institutional investors.
Here is the list of recent funding rounds of MeiraGTx:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Oct 30, 2023 | 7954304 | Post IPO | 7172439 | 2202791 | 2281630 | 9019929 |
Feb 27, 2019 | 1002362 | Post IPO | 6032978 | 6344461 | 6529604 |
Access funding benchmarks and valuations. Sign up today!View details of MeiraGTx's funding rounds and investors
MeiraGTx's founders and board of directors
Founder? Claim ProfileThe founders of MeiraGTx is Sam Waksal.
Here are the details of MeiraGTx's key team members:
- Sam Waksal: Founder & CEO of MeiraGTx and founder of 1 other company.
View details of MeiraGTx's Founder profiles and Board Members
MeiraGTx's employee count trend
MeiraGTx has 419 employees as of Jun 26. Here is MeiraGTx's employee count trend over the years:
Uncover MeiraGTx's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
MeiraGTx's Competitors and alternates
Top competitors of MeiraGTx include Jazz Pharmaceuticals, Alnylam and Sana Biotechnology. Here is the list of Top 10 competitors of MeiraGTx, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd | Alnylam 2002, Cambridge (United States), Public | Developer of RNA interference-based therapeutics for multiple disorders | $17M | 79/100 | |
3rd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 75/100 | |
4th | Spark Therapeutics 2013, Philadelphia (United States), Acquired | Developer of gene therapy for rare diseases | $82.8M | 73/100 | |
5th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 72/100 | |
6th | Denali Therapeutics 2015, San Francisco (United States), Public | Developer of therapies to treat neurodegenerative diseases | $347M | 72/100 | |
7th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
8th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
9th | Karyopharm 2008, Newton (United States), Public | Biopharmaceutical company focused on developing and commercializing innovative cancer therapies | $98.4M | 71/100 | |
10th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
92nd | MeiraGTx 2015, New York City (United States), Public | Developer of gene therapies for ocular and neurodegenerative diseases | - | 65/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on MeiraGTx's competitors? Click here to see the top ones
MeiraGTx's Investments and acquisitions
MeiraGTx has made no investments or acquisitions yet.
Reports related to MeiraGTx
Here is the latest report on MeiraGTx's sector:
News related to MeiraGTx
Filter this listMedia has covered MeiraGTx for a total of 14 events in the last 1 year, 4 of them have been about company updates.
•
MeiraGTx Announces $400 Million Strategic Investment by Oberland CapitalGlobeNewswire•Jul 07, 2026•MeiraGTx, Oberland Capital
•
MeiraGTx Reports First Quarter 2026 Financial and Operational ResultsGlobeNewswire•May 14, 2026•MeiraGTx
•
•
MeiraGTx to Present 3-Year Data from Phase 1 AQUAx Study for Radiation-Induced XerostomiaGlobeNewswire•Apr 14, 2026•MeiraGTx
•
MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1GlobeNewswire•Mar 26, 2026•MeiraGTx
•
MeiraGTx Reports Q3 2025 Results, Enters Ophthalmology Collaboration With Eli LillyGlobeNewswire•Nov 13, 2025•MeiraGTx
•
Eli Lilly Acquires MeiraGTx's Gene Therapy Program for LCA4 After Adverum BuyEyewire•Nov 11, 2025•MeiraGTx, Lilly, Monteverde, Anywhere Real Estate and 6 others
•
Worth Venture Partners LLC Invests $217,000 in MeiraGTx Holdings PLC $MGTXMarketBeat•Aug 27, 2025•MeiraGTx, Worth Venture
•
MeiraGTx Holdings PLC $MGTX Shares Acquired by Erste Asset Management GmbHMarketBeat•Aug 23, 2025•ERSTE, MeiraGTx
•
MeiraGTx Reports Second Quarter 2025 Financial and Operational ResultsGlobeNewswire•Aug 14, 2025•MeiraGTx
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about MeiraGTx
Explore our recently published companies
- Forward Media - Germany based, Unfunded company
- Cinux - 2012 founded, Unfunded company
- St Cloud Technical - St. Cloud based, 1948 founded, Funding Raised company
- Fira - Indonesia based, 2015 founded, Unfunded company
- Antigravity Investments - Berkeley based, 2016 founded, Funding Raised company
- Clear Dynamics - Series B company
